Alafair Biosciences

Alafair Biosciences is a commercial-stage medical device company focused on regenerative medicine and wound healing. It has successfully brought its core hydrogel platform to market with the FDA-cleared VersaWrap product line, which addresses the significant clinical challenge of soft-tissue adhesion and tethering following surgery. The company targets orthopedic, plastic, and reconstructive surgical markets with a naturally-derived, resorbable barrier technology. Its current commercial efforts are centered on driving surgeon adoption and expanding applications for its established platform.

Proprietary hydrogel platform based on naturally-derived biopolymers (hyaluronic acid and alginate) engineered to create bioresorbable, conformable, permeable barriers that prevent soft-tissue adhesions and tethering.

Alafair competes in the soft-tissue adhesion prevention segment against established synthetic barrier films (e.g., Gore-Tex), gel/spray formulations, and other absorbable sheets. Its differentiation is based on the unique material properties of its natural hydrogel, which is conformable, non-swelling, and bioresorbable. It must compete for market share against larger medical device companies with extensive sales forces and surgeon relationships.